Ayala Pharmaceuticals Statistics
Total Valuation
Ayala Pharmaceuticals has a market cap or net worth of 1.33 million. The enterprise value is 4.77 million.
| Market Cap | 1.33M |
| Enterprise Value | 4.77M |
Important Dates
The last earnings date was Wednesday, November 20, 2024.
| Earnings Date | Nov 20, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Ayala Pharmaceuticals has 49.30 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 49.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 1.61% |
| Float | 24.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.51 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.10 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.30
| Current Ratio | 0.30 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -181.05% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 619 |
| Profits Per Employee | -2.29M |
| Employee Count | 21 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.86% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -86.86% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 63.18 |
| Average Volume (20 Days) | 1,910 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Ayala Pharmaceuticals had revenue of 13,000 and -48.07 million in losses. Loss per share was -7.99.
| Revenue | 13,000 |
| Gross Profit | n/a |
| Operating Income | -35.27M |
| Pretax Income | -51.98M |
| Net Income | -48.07M |
| EBITDA | -34.90M |
| EBIT | -35.27M |
| Loss Per Share | -7.99 |
Balance Sheet
The company has 4.88 million in cash and 8.32 million in debt, giving a net cash position of -3.43 million or -0.07 per share.
| Cash & Cash Equivalents | 4.88M |
| Total Debt | 8.32M |
| Net Cash | -3.43M |
| Net Cash Per Share | -0.07 |
| Equity (Book Value) | -24.42M |
| Book Value Per Share | -2.05 |
| Working Capital | -17.49M |
Cash Flow
| Operating Cash Flow | -29.49M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -271,276.92% |
| Pretax Margin | -399,876.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ayala Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -29,580.09% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ayala Pharmaceuticals has an Altman Z-Score of -24.81. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -24.81 |
| Piotroski F-Score | n/a |